Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions

Cancer Biotherapy and Radiopharmaceuticals

Volumn 29, Issue 4, 2014, Pages 153-161

  Bernstein, Michael B ^a   Garnett, Charlie T ^b   Zhang, Huogang ^a   Velcich, Anna ^a   Wattenberg, Max M ^c   Gameiro, Sofia R ^c   Kalnicki, Shalom ^a   Hodge, James W ^c   Guha, Chandan ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Immunomodulator; Immunotherapy; Irradiation; Preclinical study; Prostate cancer

Indexed keywords

CD134 ANTIGEN; CD137 LIGAND; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INDUCIBLE T CELL COSTIMULATOR LIGAND; OX40 LIGAND; PROGRAMMED DEATH 1 LIGAND 1; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR IMMUNITY; UPREGULATION; ANIMAL; C57BL MOUSE; IMMUNOLOGY; MALE; PATHOLOGY; PROSTATIC NEOPLASMS; RADIATION RESPONSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; HUMANS; MALE; MICE, INBRED C57BL; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84900499259     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2013.1578     Document Type: Article

References (39)

1. Garnett CT, Palena C, Chakraborty M, et al. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004;64:7985.
2. Zhang B, Bowerman NA, Salama JK, et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 2007;204:49.
3. Lugade AA, Moran JP, Gerber SA, et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005;174:7516.
4. Nesslinger NJ, Sahota RA, Stone B, et al. Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res 2007;13:1493.
5. Schaue D, Comin-Anduix B, Ribas A, et al. T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res 2008;14:4883.
6. Lechleider RJ, Arlen PM, Tsang KY, et al. Safety and immunologic response of a viral vaccine to prostatespecific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res 2008;14:5284.
7. Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005;11:3353.
8. Kaufman HL, Divgi CR. Optimizing prostate cancer treatment by combining local radiation therapy with systemic vaccination. Clin Cancer Res 2005;11(19 Pt 1):6757.
9. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012;12:278.
10. George S, Pili R, Carducci MA, et al. Role of immunotherapy for renal cell cancer in 2011. J Natl Compr Canc Netw 2011;9:1011.
11. Akaza H, Tsukamoto T, Fujioka T, et al. Combined immunotherapy with low-dose IL-2 plus IFN-Alpha for metastatic renal cell carcinoma: Survival benefit for selected patients with lung metastasis and serum sodium level. Jpn J Clin Oncol 2011;41:1023.
12. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6:836.
13. May KF, Jr., Gulley JL, Drake CG, et al. Prostate cancer immunotherapy. Clin Cancer Res 2011;17:5233.
14. Kroczek RA, Mages HW, Hutloff A. Emerging paradigms of T-cell co-stimulation. Curr Opin Immunol 2004;16:321.
15. Keller AM, Schildknecht A, Xiao Y, et al. Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8 + T cell tolerance and permits effective immunity. Immunity 2008;29:934.
16. Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-Tumor immunity. Immunol Rev 2009;229:126.
17. Kober J, Leitner J, Klauser C, et al. The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur J Immunol 2008;38:2678.
18. Baitsch L, Legat A, Barba L, et al. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One 2012;7:e30852.
19. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/ B7-H1(PD-L1) pathway to activate anti-Tumor immunity. Curr Opin Immunol 2012;24:207.
20. Chen J, Feng Y, Lu L, et al. Interferon-gamma-induced PDL1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Immunobiology 2012;217:385.
21. Schoop R, Wahl P, Le Hir M, et al. Suppressed T-cell activation by IFN-gamma-induced expression of PD-L1 on renal tubular epithelial cells. Nephrol Dial Transplant 2004;19:2713.
22. Hannan R, Zhang H, Wallecha A, et al. Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer. Cancer Immunol Immunother 2012;61:2227.
23. Shahabi V, Reyes-Reyes M, Wallecha A, et al. Development of a Listeria monocytogenes based vaccine against prostate cancer. Cancer Immunol Immunother 2008;57:1301.
24. Tsang KY, Zaremba S, Nieroda CA, et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87:982.
25. Tsang KY, Zhu M, Nieroda CA, et al. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. Clin Cancer Res 1997;3(12 Pt 1):2439.
26. Eppihimer MJ, Gunn J, Freeman GJ, et al. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation 2002;9:133.
27. English K, Barry FP, Field-Corbett CP, et al. IFN-gamma and TNF-Alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett 2007;110:91.
28. Rowe JH, Ertelt JM, Way SS. Innate IFN-gamma is essential for programmed death ligand-1-mediated T cell stimulation following Listeria monocytogenes infection. J Immunol 2012;189:876.
29. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010;236:219.
30. KeirME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677.
31. Harris TJ, Hipkiss EL, Borzillary S, et al. Radiotherapy augments the immune response to prostate cancer in a timedependent manner. Prostate 2008;68:1319.
32. Schaue D, Ratikan JA, Iwamoto KS, et al. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 2012;83:1306.
33. Burocchi A, Pittoni P, Gorzanelli A, et al. Intratumor OX40 stimulation inhibits IRF1 expression and IL-10 production by Treg cells while enhancing CD40L expression by effector memory T cells. Eur J Immunol 2011;41:3615.
34. Gelbard A, Garnett CT, Abrams SI, et al. Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res 2006;12:1897.
35. Wilcox RA, Tamada K, Strome SE, et al. Signaling through NK cell-Associated CD137 promotes both helper function for CD8 + cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol 2002;169:4230.
36. Cannons JL, Lau P, Ghumman B, et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol 2001;167:1313.
37. Croft M, So T, Duan W, et al. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev 2009;229:173.
38. Galluzzi L, Senovilla L, Zitvogel L, et al. The secret ally: Immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012;11:215.
39. Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013;31:51.